1 Introduction to Research & Analysis Reports
1.1 Blood Clotting Accelerant Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Blood Clotting Accelerant Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Blood Clotting Accelerant Overall Market Size
2.1 Global Blood Clotting Accelerant Market Size: 2022 VS 2029
2.2 Global Blood Clotting Accelerant Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Blood Clotting Accelerant Sales: 2018-2029
3 Company Landscape
3.1 Top Blood Clotting Accelerant Players in Global Market
3.2 Top Global Blood Clotting Accelerant Companies Ranked by Revenue
3.3 Global Blood Clotting Accelerant Revenue by Companies
3.4 Global Blood Clotting Accelerant Sales by Companies
3.5 Global Blood Clotting Accelerant Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Blood Clotting Accelerant Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Blood Clotting Accelerant Product Type
3.8 Tier 1, Tier 2 and Tier 3 Blood Clotting Accelerant Players in Global Market
3.8.1 List of Global Tier 1 Blood Clotting Accelerant Companies
3.8.2 List of Global Tier 2 and Tier 3 Blood Clotting Accelerant Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Blood Clotting Accelerant Market Size Markets, 2022 & 2029
4.1.2 Powder
4.1.3 Solution
4.2 By Type – Global Blood Clotting Accelerant Revenue & Forecasts
4.2.1 By Type – Global Blood Clotting Accelerant Revenue, 2018-2023
4.2.2 By Type – Global Blood Clotting Accelerant Revenue, 2024-2029
4.2.3 By Type – Global Blood Clotting Accelerant Revenue Market Share, 2018-2029
4.3 By Type – Global Blood Clotting Accelerant Sales & Forecasts
4.3.1 By Type – Global Blood Clotting Accelerant Sales, 2018-2023
4.3.2 By Type – Global Blood Clotting Accelerant Sales, 2024-2029
4.3.3 By Type – Global Blood Clotting Accelerant Sales Market Share, 2018-2029
4.4 By Type – Global Blood Clotting Accelerant Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Blood Clotting Accelerant Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Specialty Clinics
5.1.4 Diagnostic Laboratories
5.1.5 Research Institutes
5.2 By Application – Global Blood Clotting Accelerant Revenue & Forecasts
5.2.1 By Application – Global Blood Clotting Accelerant Revenue, 2018-2023
5.2.2 By Application – Global Blood Clotting Accelerant Revenue, 2024-2029
5.2.3 By Application – Global Blood Clotting Accelerant Revenue Market Share, 2018-2029
5.3 By Application – Global Blood Clotting Accelerant Sales & Forecasts
5.3.1 By Application – Global Blood Clotting Accelerant Sales, 2018-2023
5.3.2 By Application – Global Blood Clotting Accelerant Sales, 2024-2029
5.3.3 By Application – Global Blood Clotting Accelerant Sales Market Share, 2018-2029
5.4 By Application – Global Blood Clotting Accelerant Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Blood Clotting Accelerant Market Size, 2022 & 2029
6.2 By Region – Global Blood Clotting Accelerant Revenue & Forecasts
6.2.1 By Region – Global Blood Clotting Accelerant Revenue, 2018-2023
6.2.2 By Region – Global Blood Clotting Accelerant Revenue, 2024-2029
6.2.3 By Region – Global Blood Clotting Accelerant Revenue Market Share, 2018-2029
6.3 By Region – Global Blood Clotting Accelerant Sales & Forecasts
6.3.1 By Region – Global Blood Clotting Accelerant Sales, 2018-2023
6.3.2 By Region – Global Blood Clotting Accelerant Sales, 2024-2029
6.3.3 By Region – Global Blood Clotting Accelerant Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Blood Clotting Accelerant Revenue, 2018-2029
6.4.2 By Country – North America Blood Clotting Accelerant Sales, 2018-2029
6.4.3 US Blood Clotting Accelerant Market Size, 2018-2029
6.4.4 Canada Blood Clotting Accelerant Market Size, 2018-2029
6.4.5 Mexico Blood Clotting Accelerant Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Blood Clotting Accelerant Revenue, 2018-2029
6.5.2 By Country – Europe Blood Clotting Accelerant Sales, 2018-2029
6.5.3 Germany Blood Clotting Accelerant Market Size, 2018-2029
6.5.4 France Blood Clotting Accelerant Market Size, 2018-2029
6.5.5 U.K. Blood Clotting Accelerant Market Size, 2018-2029
6.5.6 Italy Blood Clotting Accelerant Market Size, 2018-2029
6.5.7 Russia Blood Clotting Accelerant Market Size, 2018-2029
6.5.8 Nordic Countries Blood Clotting Accelerant Market Size, 2018-2029
6.5.9 Benelux Blood Clotting Accelerant Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Blood Clotting Accelerant Revenue, 2018-2029
6.6.2 By Region – Asia Blood Clotting Accelerant Sales, 2018-2029
6.6.3 China Blood Clotting Accelerant Market Size, 2018-2029
6.6.4 Japan Blood Clotting Accelerant Market Size, 2018-2029
6.6.5 South Korea Blood Clotting Accelerant Market Size, 2018-2029
6.6.6 Southeast Asia Blood Clotting Accelerant Market Size, 2018-2029
6.6.7 India Blood Clotting Accelerant Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Blood Clotting Accelerant Revenue, 2018-2029
6.7.2 By Country – South America Blood Clotting Accelerant Sales, 2018-2029
6.7.3 Brazil Blood Clotting Accelerant Market Size, 2018-2029
6.7.4 Argentina Blood Clotting Accelerant Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Blood Clotting Accelerant Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Blood Clotting Accelerant Sales, 2018-2029
6.8.3 Turkey Blood Clotting Accelerant Market Size, 2018-2029
6.8.4 Israel Blood Clotting Accelerant Market Size, 2018-2029
6.8.5 Saudi Arabia Blood Clotting Accelerant Market Size, 2018-2029
6.8.6 UAE Blood Clotting Accelerant Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Merck KgaA
7.1.1 Merck KgaA Company Summary
7.1.2 Merck KgaA Business Overview
7.1.3 Merck KgaA Blood Clotting Accelerant Major Product Offerings
7.1.4 Merck KgaA Blood Clotting Accelerant Sales and Revenue in Global (2018-2023)
7.1.5 Merck KgaA Key News & Latest Developments
7.2 Baxter International Inc
7.2.1 Baxter International Inc Company Summary
7.2.2 Baxter International Inc Business Overview
7.2.3 Baxter International Inc Blood Clotting Accelerant Major Product Offerings
7.2.4 Baxter International Inc Blood Clotting Accelerant Sales and Revenue in Global (2018-2023)
7.2.5 Baxter International Inc Key News & Latest Developments
7.3 CSL Ltd., Inc.
7.3.1 CSL Ltd., Inc. Company Summary
7.3.2 CSL Ltd., Inc. Business Overview
7.3.3 CSL Ltd., Inc. Blood Clotting Accelerant Major Product Offerings
7.3.4 CSL Ltd., Inc. Blood Clotting Accelerant Sales and Revenue in Global (2018-2023)
7.3.5 CSL Ltd., Inc. Key News & Latest Developments
7.4 Grifols International SA
7.4.1 Grifols International SA Company Summary
7.4.2 Grifols International SA Business Overview
7.4.3 Grifols International SA Blood Clotting Accelerant Major Product Offerings
7.4.4 Grifols International SA Blood Clotting Accelerant Sales and Revenue in Global (2018-2023)
7.4.5 Grifols International SA Key News & Latest Developments
7.5 Kedrion S.P.A.
7.5.1 Kedrion S.P.A. Company Summary
7.5.2 Kedrion S.P.A. Business Overview
7.5.3 Kedrion S.P.A. Blood Clotting Accelerant Major Product Offerings
7.5.4 Kedrion S.P.A. Blood Clotting Accelerant Sales and Revenue in Global (2018-2023)
7.5.5 Kedrion S.P.A. Key News & Latest Developments
7.6 Novo Nordisk A/S
7.6.1 Novo Nordisk A/S Company Summary
7.6.2 Novo Nordisk A/S Business Overview
7.6.3 Novo Nordisk A/S Blood Clotting Accelerant Major Product Offerings
7.6.4 Novo Nordisk A/S Blood Clotting Accelerant Sales and Revenue in Global (2018-2023)
7.6.5 Novo Nordisk A/S Key News & Latest Developments
7.7 Octapharma AG
7.7.1 Octapharma AG Company Summary
7.7.2 Octapharma AG Business Overview
7.7.3 Octapharma AG Blood Clotting Accelerant Major Product Offerings
7.7.4 Octapharma AG Blood Clotting Accelerant Sales and Revenue in Global (2018-2023)
7.7.5 Octapharma AG Key News & Latest Developments
7.8 PeproTech, Inc.
7.8.1 PeproTech, Inc. Company Summary
7.8.2 PeproTech, Inc. Business Overview
7.8.3 PeproTech, Inc. Blood Clotting Accelerant Major Product Offerings
7.8.4 PeproTech, Inc. Blood Clotting Accelerant Sales and Revenue in Global (2018-2023)
7.8.5 PeproTech, Inc. Key News & Latest Developments
7.9 ACROBiosystems
7.9.1 ACROBiosystems Company Summary
7.9.2 ACROBiosystems Business Overview
7.9.3 ACROBiosystems Blood Clotting Accelerant Major Product Offerings
7.9.4 ACROBiosystems Blood Clotting Accelerant Sales and Revenue in Global (2018-2023)
7.9.5 ACROBiosystems Key News & Latest Developments
8 Global Blood Clotting Accelerant Production Capacity, Analysis
8.1 Global Blood Clotting Accelerant Production Capacity, 2018-2029
8.2 Blood Clotting Accelerant Production Capacity of Key Manufacturers in Global Market
8.3 Global Blood Clotting Accelerant Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Blood Clotting Accelerant Supply Chain Analysis
10.1 Blood Clotting Accelerant Industry Value Chain
10.2 Blood Clotting Accelerant Upstream Market
10.3 Blood Clotting Accelerant Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Blood Clotting Accelerant Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
世界の血液凝固促進剤市場予測2023-2029：粉末、溶液 |
| 【英語タイトル】Blood Clotting Accelerant Market, Global Outlook and Forecast 2023-2029 | |
 | ・商品コード：MMG23JU5725 ・発行会社（調査会社）：Market Monitor Global ・発行日：2023年6月 ・ページ数：72 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後2-3営業日） ・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど ・産業分野：医薬品＆医療 |
| Single User（1名様閲覧用） | USD3,250 ⇒換算￥494,000 | 見積依頼/購入/質問フォーム |
| Multi User（20名様閲覧用） | USD4,225 ⇒換算￥642,200 | 見積依頼/購入/質問フォーム |
| Enterprise User（閲覧人数制限なし） | USD4,875 ⇒換算￥741,000 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| 当調査レポートは次の情報を含め、世界の血液凝固促進剤市場規模と予測を収録しています。・世界の血液凝固促進剤市場：売上、2018年-2023年、2024年-2029年 ・世界の血液凝固促進剤市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の血液凝固促進剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「粉末」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 血液凝固促進剤のグローバル主要企業は、Merck KgaA、 Baxter International Inc、 CSL Ltd., Inc.、 Grifols International SA、 Kedrion S.P.A.、 Novo Nordisk A/S、 Octapharma AG、 PeproTech, Inc.、 ACROBiosystemsなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、血液凝固促進剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の血液凝固促進剤市場：タイプ別、2018年-2023年、2024年-2029年 世界の血液凝固促進剤市場：タイプ別市場シェア、2022年 ・粉末、溶液 世界の血液凝固促進剤市場：用途別、2018年-2023年、2024年-2029年 世界の血液凝固促進剤市場：用途別市場シェア、2022年 ・病院、専門診療所、検査機関、研究機関 世界の血液凝固促進剤市場：地域・国別、2018年-2023年、2024年-2029年 世界の血液凝固促進剤市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における血液凝固促進剤のグローバル売上、2018年-2023年 ・主要企業における血液凝固促進剤のグローバル売上シェア、2022年 ・主要企業における血液凝固促進剤のグローバル販売量、2018年-2023年 ・主要企業における血液凝固促進剤のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Merck KgaA、 Baxter International Inc、 CSL Ltd., Inc.、 Grifols International SA、 Kedrion S.P.A.、 Novo Nordisk A/S、 Octapharma AG、 PeproTech, Inc.、 ACROBiosystems ************************************************************* ・調査・分析レポートの概要 血液凝固促進剤市場の定義 市場セグメント 世界の血液凝固促進剤市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の血液凝固促進剤市場規模 世界の血液凝固促進剤市場規模：2022年 VS 2029年 世界の血液凝固促進剤市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの血液凝固促進剤の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の血液凝固促進剤製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：粉末、溶液 血液凝固促進剤のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、専門診療所、検査機関、研究機関 血液凝固促進剤の用途別グローバル売上・予測 ・地域別市場分析 地域別血液凝固促進剤市場規模 2022年と2029年 地域別血液凝固促進剤売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Merck KgaA、 Baxter International Inc、 CSL Ltd., Inc.、 Grifols International SA、 Kedrion S.P.A.、 Novo Nordisk A/S、 Octapharma AG、 PeproTech, Inc.、 ACROBiosystems ... |
Blood clotting accelerants are used to enhance the process of blood clotting within a shorter period of time than it would require normally. Blood clotting is a complex mechanism which involves various factors and normal coagulation functioning in a patient is screened by tests prior to surgeries. The use of blood clotting accelerant is increasing in clinical spheres as a result of increasing incidence of conditions like hemophilia, anemia, thrombolysis, pulmonary embolism (PE), deep vein thrombosis (DVT), liver diseases, surgical treatments and genetically inherited deficiencies which impede normal coagulation process and can be confirmed via blood clotting accelerants. According to the National Hemophilia Foundation, von Willebrand disease affects up to 1% of US population. Current gene therapy research trials are focused on methods to insert factor VIII genes into hemophilic patients to restore normal coagulation functioning.
This report aims to provide a comprehensive presentation of the global market for Blood Clotting Accelerant, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Blood Clotting Accelerant. This report contains market size and forecasts of Blood Clotting Accelerant in global, including the following market information:
Global Blood Clotting Accelerant Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Blood Clotting Accelerant Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Blood Clotting Accelerant companies in 2022 (%)
The global Blood Clotting Accelerant market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Powder Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Blood Clotting Accelerant include Merck KgaA, Baxter International Inc, CSL Ltd., Inc., Grifols International SA, Kedrion S.P.A., Novo Nordisk A/S, Octapharma AG, PeproTech, Inc. and ACROBiosystems, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Blood Clotting Accelerant manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Blood Clotting Accelerant Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Blood Clotting Accelerant Market Segment Percentages, by Type, 2022 (%)
Powder
Solution
Global Blood Clotting Accelerant Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Blood Clotting Accelerant Market Segment Percentages, by Application, 2022 (%)
Hospitals
Specialty Clinics
Diagnostic Laboratories
Research Institutes
Global Blood Clotting Accelerant Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Blood Clotting Accelerant Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Blood Clotting Accelerant revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Blood Clotting Accelerant revenues share in global market, 2022 (%)
Key companies Blood Clotting Accelerant sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Blood Clotting Accelerant sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck KgaA
Baxter International Inc
CSL Ltd., Inc.
Grifols International SA
Kedrion S.P.A.
Novo Nordisk A/S
Octapharma AG
PeproTech, Inc.
ACROBiosystems
Outline of Major Chapters:
Chapter 1: Introduces the definition of Blood Clotting Accelerant, market overview.
Chapter 2: Global Blood Clotting Accelerant market size in revenue and volume.
Chapter 3: Detailed analysis of Blood Clotting Accelerant manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Blood Clotting Accelerant in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Blood Clotting Accelerant capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
❖ レポートの目次 ❖
| ★調査レポート[世界の血液凝固促進剤市場予測2023-2029：粉末、溶液] (コード：MMG23JU5725)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の血液凝固促進剤市場予測2023-2029：粉末、溶液]についてメールでお問い合わせ |
